Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders

NCT00992732 is registered in ClinicalTrials.gov with HemaQuest Pharmaceuticals Inc. as lead sponsor.

NCT NCT00992732
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00992732 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Open-Label Multi-Center Study Evaluating HQK-1004 Administered With Valganciclovir in Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Lymphoid Malignancies or Lymphoproliferative Disorders
Lead sponsor
HemaQuest Pharmaceuticals Inc.
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2010
Completion date
Not reported
Enrollment
1 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoid malignancies, lymphoproliferative disorders